Table 1 Concurrent pembrolizumab and RT (n = 21)
Characteristic | Median (range) or n (%) | |
|---|---|---|
Patient characteristic | ||
Female | 7 (33%) | |
Male | 14 (67%) | |
Age at diagnosis of BM, y | 67 (32-84) | |
Melanoma-specific GPA score | 3 (1-4) | |
Karnofsky performance status | 90 (80-90) | |
Median no. of BM treated w/SRS | 1.5 (1-5) | |
Median BM diameter (maximum axial), cm | 1.0 (0.2 - 2.4) | |
No. with non-brain metastases | 19/21 | |
No. with prior systemic therapy | 13/21 | |
Ipilimumab | 10/13 | |
No. with BRAF directed therapy | 5/21 | |
No. with elevated LDH | 3/12 | |
Treatment characteristic | ||
No. with single fraction SRS | 11 (52%) | |
21 Gy, # lesions | 19 | |
20 Gy, # lesions | 1 | |
18 Gy, # lesions | 3 | |
No. with post-op RT (5 treatments) | 7 (33%) | |
No. with whole brain RT | 3 (14%) | |
Pembrolizumab dosage | ||
2 mg/kg | 18 (86%) | |
10 mg/kg | 3 (14%) | |
No. of pembro doses | 6.5 (1-38) | |